Adherence to available clinical practice guidelines for initiation of antihypertensive medication in patients with or without diabetes mellitus and other comorbidities in Taiwan

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 576-585

  Chou, Chih Chieh ^a   Lin, Wei Shiang ^a   Kao, Tung Wei ^a   Chang, Yaw Wen ^a   Chen, Wei Liang ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Antihypertensive agents; diabetes; hypertension; prescription patterns

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHILD; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; TAIWAN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; INFANT; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TAIWAN; YOUNG ADULT;

EID: 84859044001     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011398658     Document Type: Article

References (62)

1. Deedwania PC. Pharmacotherapy of hypertension in patients with diabetes mellitus. Expert Opin Pharmacother. 2001;2:1805-1816. (Pubitemid 33069475)
2. Johnson ML, Singh H. Patterns of antihypertensive therapy among patients with diabetes. J Gen Intern Med. 2005;20:842-846. (Pubitemid 41725700)
3. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
4. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652. (Pubitemid 28108434)
5. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;11:1963-1974.
6. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616. (Pubitemid 29087980)
7. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;4:597-603. (Pubitemid 28172941)
8. Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. Br Med J. 1992;305:981-985.
9. Lacourciere Y, Nadeau A, Poirier L, Tancrede G. Captopril orconventional therapy in hypertensive type II diabetics: three-year analysis. Hypertension. 1993;21:786-794. (Pubitemid 23171641)
10. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. New Engl J Med. 2001;345:870-878.
11. Dicpinigaitis PV. Antiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:169S-173S. (Pubitemid 43265218)
12. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
13. Report ofthe Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National Heart, Lung, and Blood Institute, National High Blood Pressure Program; 1977.
14. 1980 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980;140:1280-1285.
15. 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984;144:1045-1057.
16. 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988;148:1023-1038.
17. Fifth Report of the Joint National Committee on Detection Evaluation, Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
18. Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
19. Guo JD, Liu GG, Christensen DB, Fu AZ. How well have practices followed guidelines in prescribing antihypertensive drugs: the role of health insurance. Value Health. 2003;6: 18-28. (Pubitemid 36228346)
20. Chou CC, Hu KY, Wu NR, Cheng YH, Loh CH, Yeh MK. Changes indrug prescription utilization for diabetic and hypertensive outpatients after initiation of the National Health Insurance's Global Budget Program in Taiwan. Med Sci Monit. 2008;14:PH33-PH39. (Pubitemid 351679880)
21. Chou CC, Lee MS, Ke CH, Chung MH. Prescription patterns of hypertension-National Health Insurance in Taiwan. J Chin Med Assoc. 2004;67:123-130. (Pubitemid 38679005)
22. Guo JD, Liu GG, Christensen DB, Fu AZ. How well have practices followed guidelines in prescribing antihypertensive drugs: the role of health insurance. Value Health. 2003;6:18-28. (Pubitemid 36228346)
23. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lesser DS. A physician survey of the effect of drug sample availability on physician's behavior. J Gen Intern Med. 2000;15:478-483. (Pubitemid 30640259)
24. Xu KT, Moloney M, Phillips S. Economics of suboptimal drug use: cost-savings of using JNC recommended medications for management of uncomplicated essential hypertension. Am J Manag Care. 2003;9:529-536. (Pubitemid 37028362)
25. Liu PH, Wang JD. Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan. BMC Health Serv Res. 2008;8: 133-144.
26. Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006;48:846-852. (Pubitemid 44610996)
27. Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol. 2004;60:135-142. (Pubitemid 38626444)
28. Kabir Z, Feely J, Bennett K. Primary care prescribing patterns in Ireland after the publication of large hypertension trials. Br J Clin Pharmacol. 2007;64:381-385. (Pubitemid 47283863)
29. McLean DL, Simpson SH, McAlister FA, Tsuyuki RT. Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies. Can J Cardiol. 2006;22:855-860. (Pubitemid 44488023)
30. McAlister FA, Campbell NR, Duong-Hua M, Chen Z, Tu K. Antihypertensive medication prescribing in27,822 elderly Canadians with diabetes over the past decade. Diabetes Care. 2006;29:836-841. (Pubitemid 44115303)
31. Cheng SH, Chiang TL. The effect of universal health insurance on health care utilization in Taiwan. JAMA. 1997;278:89-93.
32. National Health Research Institute. Contents of National Health Insurance Research Database. http://www.nhri.org.tw/nhird/data.htm. Accessed May 15, 2002.
33. Chen ZQ. Medical services in prison [in Chinese]. Family Medicine and Primary Medical Care. 2009;24:444-448.
34. Department of Health (Taiwan): Essential statistical data of national health insurance. http://www.doh.gov.tw/statistic/english/5-2/1.xls. Accessed September 7, 2009.
35. American Medical Association. Physicians' Current Procedural Terminology. Chicago, Ill: American Medical Association; 1997.
36. Bureau of National Health Insurance. Guidelines of Filing Claims for Health Service Providers. Taipei, Taiwan: Bureau of National Health Insurance; 1995.
37. Bureau of National Health Insurance. Fee Schedule of National Health Insurance. Taipei, Taiwan: Bureau of National Health Insurance; 1997.
38. Chiang CW, Chen CY, Chiu HF, Wu HL, Yang CY. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf. 2007;16:412-421.
39. Bureau of National Health Insurance. Providing Data of National Health Insurance. Department of Health, Taiwan; 1999. NHI publication No. 88041782.
40. Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA. 1990;263:407-413. (Pubitemid 20026015)
41. Chou CC, Lee MS, Ke CH, Chuang MH. Factors influencing the switch in the use of antihypertensive medications. Int J Clin Pract. 2005;59:85-91. (Pubitemid 40260120)
42. Croog SH, Levine S, Sudilovsky A, Baume RM, Clive J. Sexual symptoms inhypertensive patients: a clinical trial of antihypertensive medications. Arch Intern Med. 1988;148:788-794.
43. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314:1657-1664. (Pubitemid 16097842)
44. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes inhigh-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;23:2981-2997.
45. Punzi HA, Punzi CF. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study. Curr Hypertens Rep. 2004;6:106-110. (Pubitemid 39359550)
46. Wang TJ, Ausiello JC, Stafford RS. Trends in antihypertensive drug advertising, 1985-1996. Circulation. 1999;99:2055-2057. (Pubitemid 29183905)
47. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002;25:134-147.
48. Arauz-Pacheco C, Parrott MA, Raskin P. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26:S80-82. (Pubitemid 36928963)
49. Hypertension in people with Type 2 diabetes: knowledgebased diabetes-specific guidelines. Working Party of the International Diabetes Federation (European Region). Diabet Med. 2003;20:972-987.
50. Messerli FH, Bangalore S, Ram VS. Telmisartan, ramipril, orboth in patients at high risk of vascular events. N Engl J Med. 2008;359:426-427.
51. Chao KY, Chou P. The awareness, treatment and control of hypertension in 23 towns: Taiwan-community-based preventive medicine by Yan-Ming crusade in 1998-1993 [in Chinese]. Journal of Chinese Public Health. 1996;15:268-273.
52. Hu WY, Tseng CD, Dai YT, Chao YM. An exploration of the drug compliant behaviors and associated factors of hypertensive patients [in Chinese]. Journal of Chinese Public Health. 1996;15:319-332.
53. Stafford RS, Monti V, Furberg CD, Ma J. Long-term and shortterm changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension. 2006;48:213-218. (Pubitemid 44309814)
54. Burke TA, Venketasubramanian RN. The epidemiology of stroke in the East Asian region: a literature-based review. Int J Stroke. 2006;1:208-215. (Pubitemid 44541733)
55. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906. (Pubitemid 41265663)
56. Ford GA, Asghar MN. Management of hypertension in the elderly: attitudes of general practitioners and hospital physicians. Br J Clin Pharmacol. 1995;39:465-469.
57. Wallenius S, Kumpusala H, Parnanen TJ. Drug treatment for hypertension in Finnish primary health care. Eur J Clin Pharmacol. 1988;54:793-799.
58. Edward PR, Lunt DW, Fehrsen GS, Lombard CJ, Steyn K. Improving cost-effectiveness of hypertension management at a community health center. S Afr Med J. 1998;88:549-554. (Pubitemid 28246357)
59. Flottorp S, Oxman AD. Identifying barriers and tailoring interventions to improve the management of urinary tract infections and sore throat: a pragmatic study using qualitative methods. BMC Health Serv Res. 2003;3:3.
60. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension. 2000;36:600-603.
61. Windmeijer F, de Laat E, Douven R, Mot E. Pharmaceutical promotion and GPprescription behaviour. Health Econ. 2006;15:5-18.
62. Lin TL, Yang Kao YH, Tang CH, Wu HM, Cheng HW. Impact of introduction of angiotensin II antagonist on the antihypertensive utilization in Taiwan. J Food and Drug Analysis. 2008;16:21-29.